2007
DOI: 10.1016/j.bpc.2007.04.001
|View full text |Cite
|
Sign up to set email alerts
|

Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2008
2008
2015
2015

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(7 citation statements)
references
References 47 publications
0
7
0
Order By: Relevance
“…GSK3β is a regulatory Ser/Thr protein kinase encoded by two closely related isoforms GSK3α and GSK3β,13 and is known as essential components in glycogen metabolism, Wnt signaling, and NFκB pathways 14–16. Aberrant GSK3β activity is associated with several diseases such as cancer, diabetes, inflammation, etc,17–19 and pharmacological inhibitors of this attractive therapeutic target are getting more and more attentions 20–22…”
Section: Introductionmentioning
confidence: 99%
“…GSK3β is a regulatory Ser/Thr protein kinase encoded by two closely related isoforms GSK3α and GSK3β,13 and is known as essential components in glycogen metabolism, Wnt signaling, and NFκB pathways 14–16. Aberrant GSK3β activity is associated with several diseases such as cancer, diabetes, inflammation, etc,17–19 and pharmacological inhibitors of this attractive therapeutic target are getting more and more attentions 20–22…”
Section: Introductionmentioning
confidence: 99%
“…Pyrroloazepinones are considered important structural motifs, which are present in various natural and pharmaceutical products, such as Hymenialdisine, Paullones, and Lantonduine A (Figure ). Moreover, pyrrolo­azepinone derivatives have been identified to inhibit different protein kinases for the treatment of a variety of diseases . Owing to their biological properties, a series of powerful strategies for the synthesis of pyrrolo- and indolo-azepinones have been developed .…”
mentioning
confidence: 99%
“…First, L4 seems to belong to the large group of ATP-competitive inhibitors. This is suggested by molecular docking studies demonstrating that L4 binds to the ATP binding region and closely interacts with key residues Asp133 and Val135 that seem to be essential for the binding of many other GSK-3␤ inhibitors [12,58,72,[74][75][76][77][78]. Despite this similarity, however, L4 does inhibit neither CDKs nor PKC which are secondary targets of several ATPcompetitive inhibitors [71,74].…”
Section: Discussionmentioning
confidence: 99%